Benzothiazole formulations and use thereof

Details Benzothiazole formulations and use thereof Benzothiazole formulations and use thereof

2005-11-16

2010-11-23

Shameem, Golam M. M. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S235800, C514S367000, C544S122000, C548S152000

Reexamination Certificate

active

07838522

ABSTRACT:
The present invention is related to macrogol glyceride pharmaceutical formulations containing benzothiazole derivatives. In particular, the invention is related to benzothiazole stearoyl macrogol pharmaceutical formulations, method of preparation and use thereof.

REFERENCES:
patent: 4988679 (1991-01-01), Chavkin et al.
patent: 5433951 (1995-07-01), Serajuddin et al.
patent: 5540938 (1996-07-01), Masterson et al.
patent: 2006/0177509 (2006-08-01), Nagahara et al.
patent: 0727406 (1996-08-01), None
patent: WO 98/48802 (1998-11-01), None
patent: WO 99/55678 (1999-11-01), None
patent: WO 99/67230 (1999-12-01), None
patent: WO 01/45698 (2001-06-01), None
patent: WO 01/47920 (2001-07-01), None
patent: WO 02/28866 (2002-04-01), None
patent: WO 03/047570 (2003-06-01), None
patent: WO 03/070711 (2003-08-01), None
patent: WO 03/091249 (2003-11-01), None
patent: WO 2004/028251 (2004-04-01), None
patent: WO 2004/043965 (2004-05-01), None
patent: WO 2005/025567 (2005-03-01), None
patent: WO 2005/049192 (2005-06-01), None
Jadhav et al. [Gelucires: Pharmaceutical Applications, Pharmainfo.net 6(4) (2008) 1-11].
Golub et al. Science (1999), vol. 286 531-537.
Lala et al. Cancer and Metastasis Reviews (1998), 17(1), 91-106.
Aungst, B., et al., “Improved Oral Bioavailability of an HIV Protease Inhibitor Using Gelucire 44/14 and Labrasol Vehicles,”Bull. Tech. Gattefossé,87: 49-54 (1994).
Bruner-Tran, K., et al., “Experimental Endometriosis: The Nude Mouse as a Xenographic Host,”Annals New York Academy of Sciences, 955: 328-339 (2002).
Chabaka, L., et al., “Facile Synthesis of 2-Furyl-, 2-Pyrrolyl-, 2-Imidazolyl—and Pyrrolo-Azoles from 2-Substituted Methylazoles,”Polish Journal of Chemistry, 68: 1317-1325 (1994).
D'Antonio, M., et al., “Ability of Recombinant Human TNF Binding Protein-1 (r-hTBP-1) to Inhibit the Development of Experimentally-Induced Endometriosis in Rats,”Journal of Reproductive Immunology, 48: 81-98 (2000).
International Search Report for International Application No. PCT/EP2005/056020 dated Jun. 7, 2006.
Written Opinion of the International Searching Authority, International Application No. PCT/EP2005/056020 dated Jun. 7, 2006.
Notification Concerning Transmittal of International Preliminary Report on Patentability, and International Preliminary Report on Patentability, International Application No. PCT/EP2005/056020, mail date May 22, 2007.

Affiliated with

Also associated with

Rating

Benzothiazole formulations and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Benzothiazole formulations and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzothiazole formulations and use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4151417